medigraphic.com

2014, Número 1

<< Anterior Siguiente >>

Rev Fac Med UNAM 2014; 57 (1)


Aspergilosis traqueobronquial invasiva en un paciente con púrpura trombocitopénica trombótica tratada con Anti-CD20

Madinaveitia TJ, Aisa ÁA, Hurtado MR, Vargas VP, Vázquez GJC, Esponda PJ, Carrillo RS, Gallegos GC

Idioma: Español
Referencias bibliográficas: 26
Paginas: 31-38
Archivo PDF: 249.95 Kb.


RESUMEN

La aspergilosis invasiva es una complicación que se presenta con mayor frecuencia en pacientes con inmunosupresión. La aspergilosis traqueobronquial es una complicación muy rara con mínimas manifestaciones clínicas. Se informa de una paciente de 53 años con diagnóstico de púrpura trombocitopénica trombótica (PTT) con inmunosupresión por el uso de esteroides y anti CD-20, que presentó hemoptisis en 2 ocasiones; la segunda fue masiva y ocasionó la muerte. Previo al segundo evento de la hemoptisis se logró realizar broncoscopía, que mostró pseudomembranas y ulceración del epitelio bronquial. En el postmortem se logró documentar la presencia de Aspergillus tanto en la biopsia como en el cultivo. Es de gran importancia la sospecha y un reconocimiento temprano de esta patología en pacientes con inmunosupresión por su alta mortalidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chang SM, Kuo HT, Lin FJ, Tzen CY, Sheu CY. Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromised patients. Scand J infect Dis. 2005; 37:937-42.

  2. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore). 1970;49:147-73.

  3. Kemper CA, Hosteler JS, Follansbee SE, Ruane P, Covington DC, Leong SS, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis. 1993;7:344-52.

  4. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, Stevens DA, Theodore J. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis. 1991;144:552-6.

  5. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104.

  6. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore). 2000;79:250-60.

  7. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709.

  8. Machida U, Kami M, Kanda Y, Takeuchi K, Akahane M, Yamaguchi I, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:1145-9.

  9. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-Fatality rate: Systematic review of the literature. Clin Infect Dis. 2001;32:358-66.

  10. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.

  11. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-75.

  12. Sridhar M, Jeffers M, Brankin E, Soukop M, Banham S. Wheeze in a heart transplant patient with lymphoma. Postgrad Med J. 1995;71:375-7.

  13. Tait RC, O’Driscoll BR, Denning DW. Unilateral wheeze caused by pseudomembranous Aspergillus tracheobronchitis in the immunocompromised patient. Thorax. 1993; 48:1285-7.

  14. Gefter WB. The spectrum of pulmonary Aspergillosis. J Thorac Imaging. 1992;7:56-74.

  15. Karnak D, Avery RK, Gildea TR, Sahoo D, Mehta AC. Endobronchial fungal disease: an under-recognized entity. Respiration. 2007;74:88-104.

  16. Hines DW, Haber MH, Yaremko LS. Pseudomembranous tracheobronchitis caused by aspergillosis. Am Rev Respir Dis. 1991;143:1408-11.

  17. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71.

  18. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.

  19. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641-5.

  20. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25:1295-320.

  21. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12.

  22. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.

  23. Van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol. 2006;85:621-3.

  24. Achan V, Williams FMK, Leach RM. Pulmonary aspergillosis and massive haemoptysis in systemic lupus erythematosus. Clin Intensive Care. 1996;7:102-7.

  25. George JN, Al-Nouri ZD. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. ASH Education Program. Hematology. 2012:604-9.

  26. George JN. How I treat patients with thrombotic thrombocytopenic purpura-2010. Blood. 2010;116(20):4060-9.




2020     |     www.medigraphic.com